C.R. Bard, Inc. (NYSE:BCR) Scheduled to Post Earnings on Monday

C.R. Bard, Inc. (NYSE:BCR) will be posting its quarterly earnings results before the market opens on Monday, July 24th. Analysts expect C.R. Bard to post earnings of $2.84 per share for the quarter.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.22. The firm had revenue of $938.80 million during the quarter, compared to analysts’ expectations of $916.15 million. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.34 EPS. On average, analysts expect C.R. Bard to post $11.79 EPS for the current fiscal year and $12.93 EPS for the next fiscal year.

Shares of C.R. Bard, Inc. (NYSE BCR) opened at 322.22 on Friday. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $322.85. The firm has a market cap of $23.33 billion, a PE ratio of 41.01 and a beta of 0.59. The stock has a 50 day moving average price of $316.17 and a 200-day moving average price of $273.92.

The company also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Investors of record on Monday, July 24th will be paid a dividend of $0.26 per share. The ex-dividend date is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.32%. C.R. Bard’s payout ratio is currently 13.21%.

A number of equities analysts recently commented on BCR shares. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price for the company in a research note on Thursday, May 11th. Jefferies Group LLC reiterated a “hold” rating and set a $237.00 target price on shares of C.R. Bard in a research note on Monday, March 27th. Morgan Stanley downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BMO Capital Markets reiterated a “buy” rating and set a $255.00 target price on shares of C.R. Bard in a research note on Tuesday, April 11th. Finally, Raymond James Financial, Inc. downgraded shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Eleven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $271.31.

TRADEMARK VIOLATION WARNING: This report was originally reported by [[site]] and is owned by of [[site]]. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at [[permalink]].

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the company’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the transaction, the vice president now owns 10,139 shares in the company, valued at $3,082,256. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.80% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.